Strasbourg, France -- November 16th, 2010 - GRAFFINITY'S PROPRIETARY FRAGMENT-BASED SPR DRUG DISCOVERY TECHNOLOGY WILL BE ADDED TO NOVALIX'S INTEGRATED CHEMISTRY AND BIOPHYSICAL CAPABILITIES - NovAliX SAS (“NovAliX”) announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH ("GRAFFINITY") of Heidelberg, Germany, a leading fragment based drug discovery services company. Financial details of the transaction were not disclosed.NovAliX’ President, Stephan Jenn stated: "The acquisition of Graffinity will be a significant step toward our goal of providing integrated drug discovery services. With a unique and diverse small molecule library and patented SPR-imaging technology, the Graffinity platform is fully complementary to NovAliX’ offerings in X-Ray crystallography, supramolecular mass spectrometry and liquid-/solid-state NMR. With this second technology-oriented acquisition in 2010, we are forming a group of more than 120 scientists developing and applying cutting edge research capabilities in discovery and development of innovative medicines. We are an external innovation partner for our pharmaceutical clients."...
[...]
...About NovAliX SAS
Strasbourg, France based NovAliX Group is focusing on the development of enabling chemistry and biophysical technologies to support the pharmaceutical industry’s outsourcing needs from discovery to manufacturing. With X-ray protein crystallography, supramolecular mass spectrometry and organic chemistry NovAliX offers comprehensive integrated services in small molecule drug discovery. With advanced NMR technologies, NovAliX provides fine characterization of biologics, thorough analysis of APIs and polymorphism studies to support pharmaceutical development and manufacturing teams.
NovAliX Group, a team of 120 scientists, is located in state-of-the-art laboratory facilities in the Strasbourg-Illkirch BioParc and throughout Europe... [PDF] NovAliX's Press Release -
